Atomoxetine (Strattera)

SNRIprescriptionoral · inferred

Selective norepinephrine reuptake inhibitor approved for ADHD in children and adults. Not a stimulant, no abuse potential (non-scheduled). Active metabolite 4-hydroxyatomoxetine is equipotent at NET but present at low concentrations. Metabolized by CYP2D6, poor metabolizers have 5x higher exposure and half-life extends to ~21 hours. Takes 4-6 weeks for full ADHD effect. Also increases prefrontal dopamine via NET-mediated reuptake.

Projected serum levels — 40 mg, once daily

Maintenance schedule: 40 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 21.6 mg, trough ≈ 1.1 mg body load. Population-based estimate over 15 days for a 40 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category: SNRI
Route modeled: Oral
Model confidence: inferred
Half-life: 5.2 h
Common dose: 40 mg
Suggested maximum: 100 mg/day
Reference dose range: 10–100 mg (single dose)
Suggested cadence: once daily
Validated against: 40 mg oral — Cmax 0.35 mg/L at 1.5 h

Documented interactions

contraindicated
MDA (3,4-Methylenedioxyamphetamine) + Atomoxetine (Strattera) CYP inhibition
MDA (3,4-Methylenedioxyamphetamine) mechanism_based of CYP2D6 predicted to change Atomoxetine (Strattera) AUC by ~5.14x
contraindicated
MDMA (Ecstasy) + Atomoxetine (Strattera) CYP inhibition
MDMA (Ecstasy) mechanism_based of CYP2D6 predicted to change Atomoxetine (Strattera) AUC by ~5.14x
contraindicated
Paroxetine (Paxil) + Atomoxetine (Strattera) CYP inhibition
Paroxetine (Paxil) mechanism_based of CYP2D6 predicted to change Atomoxetine (Strattera) AUC by ~5.14x
danger
1P-LSD (1-Propionyl-LSD) + Atomoxetine (Strattera) Serotonin risk
1P-LSD (1-Propionyl-LSD) and Atomoxetine (Strattera) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
danger
25I-NBOMe + Atomoxetine (Strattera) Serotonin risk
25I-NBOMe and Atomoxetine (Strattera) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
danger
2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Atomoxetine (Strattera) Serotonin risk
2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Atomoxetine (Strattera) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…

Serum checks 279 modeled interaction pairings for atomoxetine (strattera) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled trial Michelson D et al. · Biological Psychiatry, 2003 DOI
Pivotal RCT (280 adults) establishing atomoxetine as effective for adult ADHD with significant improvement in CAARS total scores versus placebo, and maintained efficacy over 10 weeks.
Clinical pharmacokinetics of atomoxetine Sauer JM et al. · Clinical Pharmacokinetics, 2005 DOI
Comprehensive PK review establishing atomoxetine half-life of 5 hours (extensive metabolizers) versus 21 hours (poor metabolizers), CYP2D6-dependent metabolism, and active 4-hydroxy metabolite.
Effect of atomoxetine on executive function impairments in adults with ADHD. Brown TE, Holdnack J, Saylor K, Adler L, Spencer T, Williams DW, Padival AK, Schuh K, Trzepacz PT, Kelsey D · Journal of attention disorders, 2011 DOI
This citation reports a human clinical study involving Atomoxetine (Strattera). It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.

3 published studies referenced in the app, each with a plain-language summary.